Evidence map›Paper›PMID 41217771›Full record

ArticleJournal of medicinal chemistry2025

Quinoline-Based DNA Methyltransferase Inhibitors Featuring Basic Side Chains: Design, Synthesis, and Insight in Biochemical and Anticancer Cell Properties.

Clemens Zwergel, Chiara Lambona, Rossella Fioravanti, Alessia Raucci, Francesco Fiorentino, Guilaine Nchugoua Tchieh, Corinne Jallet, Laurent Lacroix, Michela Pierrettori, Francesca Romana Pellegrini and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Clemens ZwergelDepartment of Drug Chemistry and Technologies, Sapienza University of Rome, Piazzale Aldo Moro 5, Rome 00185, Italy.ORCID 0000-0002-3097-0003
Chiara LambonaDepartment of Drug Chemistry and Technologies, Sapienza University of Rome, Piazzale Aldo Moro 5, Rome 00185, Italy.ORCID 0000-0002-3415-4126
Rossella FioravantiDepartment of Drug Chemistry and Technologies, Sapienza University of Rome, Piazzale Aldo Moro 5, Rome 00185, Italy.
Alessia RaucciDepartment of Drug Chemistry and Technologies, Sapienza University of Rome, Piazzale Aldo Moro 5, Rome 00185, Italy.
Francesco FiorentinoDepartment of Drug Chemistry and Technologies, Sapienza University of Rome, Piazzale Aldo Moro 5, Rome 00185, Italy.ORCID 0000-0003-3550-1860
Guilaine Nchugoua TchiehUniversité Paris Cité, CNRS UMR no 3523 Chem4Life, Epigenetic Chemical Biology, Department of Structural Biology and Chemistry, Institut Pasteur, F-75015 Paris, France.
Corinne JalletUniversité Paris Cité, CNRS UMR no 3523 Chem4Life, Epigenetic Chemical Biology, Department of Structural Biology and Chemistry, Institut Pasteur, F-75015 Paris, France.
Laurent LacroixIBENS, Département de biologie, École Normale Supérieure, Université PSL, CNRS, INSERM, Paris 75005, France.
Michela PierrettoriIBPM Institute of Molecular Biology and Pathology, CNR National Research Council of Italy, Via degli Apuli 4, Rome 00185, Italy.
Francesca Romana PellegriniIBPM Institute of Molecular Biology and Pathology, CNR National Research Council of Italy, Via degli Apuli 4, Rome 00185, Italy.
Yan XiongMount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Science, Oncological Science and Neuroscience, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States.
Jian JinMount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Science, Oncological Science and Neuroscience, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States.ORCID 0000-0002-2387-3862
Paola ArimondoUniversité Paris Cité, CNRS UMR no 3523 Chem4Life, Epigenetic Chemical Biology, Department of Structural Biology and Chemistry, Institut Pasteur, F-75015 Paris, France.
Daniela TrisciuoglioIBPM Institute of Molecular Biology and Pathology, CNR National Research Council of Italy, Via degli Apuli 4, Rome 00185, Italy.
Antonello MaiDepartment of Drug Chemistry and Technologies, Sapienza University of Rome, Piazzale Aldo Moro 5, Rome 00185, Italy.ORCID 0000-0001-9176-2382
Sergio ValenteDepartment of Drug Chemistry and Technologies, Sapienza University of Rome, Piazzale Aldo Moro 5, Rome 00185, Italy.ORCID 0000-0002-2241-607X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The quinoline DNMT inhibitors

Indexed as

Antineoplastic AgentsDNA (Cytosine-5-)-MethyltransferasesEnzyme InhibitorsQuinolinesApoptosisCell Line, TumorCell ProliferationDNA (Cytosine-5-)-Methyltransferase 1DNA MethylationDNA Methyltransferase 3ADrug DesignDrug Screening Assays, AntitumorHCT116 CellsHumansStructure-Activity RelationshipAntineoplastic AgentsDNA (Cytosine-5-)-Methyltransferase 1DNA (Cytosine-5-)-MethyltransferasesDNA Methyltransferase 3ADNMT1 protein, humanEnzyme InhibitorsquinolineQuinolines

Identifiers

PMID41217771
PMCPMC12670401

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.